Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292380493> ?p ?o ?g. }
- W4292380493 endingPage "e062036" @default.
- W4292380493 startingPage "e062036" @default.
- W4292380493 abstract "Combination treatment with erlotinib plus bevacizumab has the potential to become a standard treatment regimen for patients with epidermal growth factor receptor mutation-positive (EGFRm+) advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of erlotinib plus bevacizumab in patients with EGFRm+ advanced NSCLC.Systematic review and meta-analysis.The PubMed, Embase, Web of Science and Cochrane Library databases were searched, from inception to 15 January 2022.We included randomised controlled trials (RCTs), reported in English, assessing the efficacy of erlotinib plus bevacizumab versus erlotinib monotherapy in patients with EGFRm+ advanced NSCLC.The main objective was to assess overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs). Two independent reviewers extracted data and assessed the risk of bias. A random-effects model was used where there was evidence for homogeneous effects.Four RCTs (reported across six publications) were included in the meta-analysis, with a total of 775 patients included in the pooled analyses of PFS, OS and ORR (387 in the erlotinib plus bevacizumab intervention group and 388 in the erlotinib group). Compared with the erlotinib alone group, the erlotinib plus bevacizumab group achieved a significantly prolonged PFS (HR: 0.59; 95% CI 0.49 to 0.72; p<0.00001; I2=0%), but OS (HR: 0.95; 95% CI 0.78 to 1.15; p=0.59; I2=0%) and ORR (OR: 1.25; 95% CI 0.89 to 1.74; p=0.19; I2=0%) were not significantly prolonged. A total of 776 cases were used for a pooled analysis of AEs. Regarding AEs, combined treatment significantly increased the incidence of diarrhoea (51% vs 43%, 95% CI 1.03 to 1.38; p=0.006), haemorrhagic events (41% vs 20%, 95% CI 1.12 to 6.31; p=0.03), proteinuria (25% vs 3%, 95% CI 4.86 to 17.66; p<0.0001) and hypertension (40% vs 8%, 95% CI 3.66 to 7.88; p<0.0001).Erlotinib plus bevacizumab for the treatment of patients with EGFRm+ advanced NSCLC was associated with significantly prolonged PFS compared with erlotinib alone, but the combination did not prolong OS." @default.
- W4292380493 created "2022-08-20" @default.
- W4292380493 creator A5002370845 @default.
- W4292380493 creator A5018917599 @default.
- W4292380493 creator A5026906414 @default.
- W4292380493 creator A5029517636 @default.
- W4292380493 creator A5048281848 @default.
- W4292380493 creator A5051288772 @default.
- W4292380493 creator A5067448001 @default.
- W4292380493 creator A5082513697 @default.
- W4292380493 creator A5090554974 @default.
- W4292380493 date "2022-08-01" @default.
- W4292380493 modified "2023-09-25" @default.
- W4292380493 title "Erlotinib plus bevacizumab versus erlotinib alone in patients with <i>EGFR</i>-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials" @default.
- W4292380493 cites W2012932483 @default.
- W4292380493 cites W2048662229 @default.
- W4292380493 cites W2098923148 @default.
- W4292380493 cites W2107328434 @default.
- W4292380493 cites W2130431075 @default.
- W4292380493 cites W2132416992 @default.
- W4292380493 cites W2136601558 @default.
- W4292380493 cites W2145703688 @default.
- W4292380493 cites W2145835533 @default.
- W4292380493 cites W2153991063 @default.
- W4292380493 cites W2171139285 @default.
- W4292380493 cites W2302258098 @default.
- W4292380493 cites W2466790346 @default.
- W4292380493 cites W2588681363 @default.
- W4292380493 cites W2593183134 @default.
- W4292380493 cites W2606131767 @default.
- W4292380493 cites W2609243345 @default.
- W4292380493 cites W2623783819 @default.
- W4292380493 cites W2757127742 @default.
- W4292380493 cites W2766812598 @default.
- W4292380493 cites W2788612690 @default.
- W4292380493 cites W2795708883 @default.
- W4292380493 cites W2800297699 @default.
- W4292380493 cites W2804337541 @default.
- W4292380493 cites W2937223370 @default.
- W4292380493 cites W2945927256 @default.
- W4292380493 cites W2961009279 @default.
- W4292380493 cites W2964471257 @default.
- W4292380493 cites W2968754080 @default.
- W4292380493 cites W2979271184 @default.
- W4292380493 cites W2987921837 @default.
- W4292380493 cites W2990041408 @default.
- W4292380493 cites W3013347515 @default.
- W4292380493 cites W3022903699 @default.
- W4292380493 cites W3038230556 @default.
- W4292380493 cites W3082446900 @default.
- W4292380493 cites W3099381320 @default.
- W4292380493 cites W3106882749 @default.
- W4292380493 cites W3109795019 @default.
- W4292380493 cites W3119005666 @default.
- W4292380493 cites W3191778845 @default.
- W4292380493 cites W3200033087 @default.
- W4292380493 cites W3212594364 @default.
- W4292380493 cites W3215491302 @default.
- W4292380493 cites W4200178351 @default.
- W4292380493 cites W4220855807 @default.
- W4292380493 cites W4245879305 @default.
- W4292380493 cites W4281260484 @default.
- W4292380493 doi "https://doi.org/10.1136/bmjopen-2022-062036" @default.
- W4292380493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35985780" @default.
- W4292380493 hasPublicationYear "2022" @default.
- W4292380493 type Work @default.
- W4292380493 citedByCount "2" @default.
- W4292380493 countsByYear W42923804932023 @default.
- W4292380493 crossrefType "journal-article" @default.
- W4292380493 hasAuthorship W4292380493A5002370845 @default.
- W4292380493 hasAuthorship W4292380493A5018917599 @default.
- W4292380493 hasAuthorship W4292380493A5026906414 @default.
- W4292380493 hasAuthorship W4292380493A5029517636 @default.
- W4292380493 hasAuthorship W4292380493A5048281848 @default.
- W4292380493 hasAuthorship W4292380493A5051288772 @default.
- W4292380493 hasAuthorship W4292380493A5067448001 @default.
- W4292380493 hasAuthorship W4292380493A5082513697 @default.
- W4292380493 hasAuthorship W4292380493A5090554974 @default.
- W4292380493 hasBestOaLocation W42923804931 @default.
- W4292380493 hasConcept C121608353 @default.
- W4292380493 hasConcept C126322002 @default.
- W4292380493 hasConcept C143998085 @default.
- W4292380493 hasConcept C168563851 @default.
- W4292380493 hasConcept C197934379 @default.
- W4292380493 hasConcept C2776256026 @default.
- W4292380493 hasConcept C2776478404 @default.
- W4292380493 hasConcept C2776694085 @default.
- W4292380493 hasConcept C2777802072 @default.
- W4292380493 hasConcept C2778087573 @default.
- W4292380493 hasConcept C2779438470 @default.
- W4292380493 hasConcept C2781413609 @default.
- W4292380493 hasConcept C2909325608 @default.
- W4292380493 hasConcept C71924100 @default.
- W4292380493 hasConcept C95190672 @default.
- W4292380493 hasConceptScore W4292380493C121608353 @default.
- W4292380493 hasConceptScore W4292380493C126322002 @default.
- W4292380493 hasConceptScore W4292380493C143998085 @default.
- W4292380493 hasConceptScore W4292380493C168563851 @default.